Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity

Figure 4 A suggested algorithm for the use of non-invasive tests for risk stratification of patients with suspected non-alcoholic fatty liver disease in clinical practice. ¹Obesity, type 2 diabetes, or metabolic syndrome; ²Estimated prevalence for low, intermediate, and high risks groups; ³Patented serum biomarkers (FibroTest, Fibrometer, or ELF) could be considered in patients with intermediate-risk. ARFI: Acoustic radiation force imaging; LSM: Liver stiffness measurement; MRE: Magnetic resonance elastography; NPV: Negative predictive value; PPV: Positive predictive value; SWE: Shear wave elastography.